| Literature DB >> 17258520 |
L V Hale1, R J Sells Galvin, J Risteli, Y L Ma, A K Harvey, X Yang, R L Cain, Q Zeng, C A Frolik, M Sato, A L Schmidt, A G Geiser.
Abstract
Serum PINP has emerged as a reliable marker of bone turnover in humans and is routinely used to monitor bone formation. However, the effects of PTH (1-34) on bone turnover have not been evaluated following short-term treatment. We present data demonstrating that PINP is an early serum biomarker in the rat for assessing bone anabolic activity in response to treatment with PTH (1-38). Rat serum PINP levels were found to increase following as few as 6 days of treatment with PTH (1-38) and these increases paralleled expression of genes associated with bone formation, as well as, later increases in BMD. Additionally, PINP levels were unaffected by treatment with an antiresorptive bisphosphonate. PINP may be used to detect PTH-induced early bone formation in the rat and may be more generally applicable for preclinical testing of potential bone anabolic drugs.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17258520 DOI： 10.1016/j.bone.2006.11.027
Source DB: PubMed Journal: Bone ISSN： 1873-2763 Impact factor: 4.398